Inhibitory effect of ARHI on pancreatic cancer cells and NF‑κB activity

Hu,Yi‑Qun; Si,Li‑Juan; Ye,Zhen‑Shi; Lin,Zhen‑He; Zhou,Jing‑Ping

doi:10.3892/mmr.2013.1342

Inhibitory effect of ARHI on pancreatic cancer cells and NF‑κB activity

Authors:
- Yi‑Qun Hu
- Li‑Juan Si
- Zhen‑Shi Ye
- Zhen‑He Lin
- Jing‑Ping Zhou
View Affiliations

Affiliations: Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian 361004, P.R. China
Published online on: February 26, 2013 https://doi.org/10.3892/mmr.2013.1342
Pages: 1180-1184

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the effect of aplasia ras homolog member I (ARHI) on proliferation, apoptosis and the cell cycle in the pancreatic cancer cell line PANC‑1. The study also aimed to examine the effect of ARHI on the activity of the nuclear factor (NF)‑κB and to determine whether ARHI acts as a tumor suppressor in the development of pancreatic cancer by inhibiting the activity of NF‑κB. A pIRES2‑EGFP‑ARHI vector, constructed by reverse transcrition (RT)‑PCR, was transiently transfected into the PANC‑1 cells and analyzed for the expression of the ARHI protein by western blotting. A MTT assay was used to quantify cell proliferation, and apoptosis was analyzed by flow cytometry. The NF‑κB signaling pathway, specifically the pathway using the nuclear phosphorylated p65 isoform, was analyzed by western blotting. Expression of the ARHI protein was detected by western blotting subsequent to the PANC‑1 cells being transiently transfected with the pIRES2‑EGFP‑ARHI construct. Cell proliferation was strongly inhibited in the PANC‑1 cells transfected with pIRES2‑EGFP‑ARHI. The cell cycle assays indicated an increase in the number of cells at the G0/G1 phase and a decrease in the cells at the S phase, but the difference was not significant (P>0.05). Time course studies also indicated a marked increase in the apoptotic index following transient transfection, as well as a gradual decrease in the expression of the nuclear phosphorylated p65 protein. ARHI acts as a tumor suppressor by downregulating the NF‑κB signaling pathway, which results in the inhibition of cell proliferation, apoptosis and the cell cycle in the pancreatic tumor PANC‑1 cell line.

View Figures

View References

1	Yu Y, Xu F, Peng H, et al: NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA. 96:214–219. 1999. View Article : Google Scholar : PubMed/NCBI
2	Herreros-Villanueva M, Hijona E, Cosme A and Bujanda L: Spontaneous regression of pancreatic cancer: real or a misdiagnosis? World J Gastroenterol. 18:2902–2908. 2012. View Article : Google Scholar : PubMed/NCBI
3	Strimpakos A, Saif MW and Syrigos KN: Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev. 27:495–522. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hisatomi H, Nagao K, Wakita K and Kohno N: ARHI/NOEY2 inactivation may be important in breast tumor pathogenesis. Oncology. 62:136–140. 2002. View Article : Google Scholar : PubMed/NCBI
5	Lu Z, Luo RZ, Lu Y, et al: The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 118:3917–3929. 2008.PubMed/NCBI
6	Feng WU, Marquez R, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y and Bast RC Jr: Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 112:1489–1502. 2008. View Article : Google Scholar : PubMed/NCBI
7	Weber F, Aldred MA, Morrison CD, et al: Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. J Clin Endocrinol Metab. 90:1149–1155. 2005. View Article : Google Scholar : PubMed/NCBI
8	Riemenschneider MJ, Reifenberger J and Reifenberger G: Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. Int J Cancer. 122:2503–2510. 2008. View Article : Google Scholar : PubMed/NCBI
9	Amaravadi RK: Autophagy-induced tumor dormancy in ovarian cancer. J Clin Invest. 118:3837–3840. 2008.PubMed/NCBI
10	Lu X, Qian J, Yu Y, Yang H and Li J: Expression of the tumor suppressor ARHI inhibits the growth of pancreatic cancer cells by inducing G1 cell cycle arrest. Oncol Rep. 22:635–640. 2009.PubMed/NCBI
11	Yang H, Lu X, Qian J, et al: Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. Mol Med Rep. 3:581–587. 2010.PubMed/NCBI
12	Wickremasinghe RG, Prentice AG and Steele AJ: p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia. 25:1400–1407. 2011. View Article : Google Scholar : PubMed/NCBI
13	Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ: Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 9:346–354. 2003.PubMed/NCBI
14	Li Q and Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol. 2:725–734. 2002. View Article : Google Scholar : PubMed/NCBI
15	Hayden MS and Ghosh S: Signaling to NF-kappaB. Genes Dev. 18:2195–2224. 2004. View Article : Google Scholar : PubMed/NCBI
16	Ma X, Yang L, Xiao L, et al: Down-regulation of EBV-LMP1 radio-sensitizes nasal pharyngeal carcinoma cells via NF-κB regulated ATM expression. PLoS One. 6:e246472011.PubMed/NCBI
17	Perona R and Sánchez-Pérez I: Control of oncogenesis and cancer therapy resistance. Br J Cancer. 90:573–577. 2004. View Article : Google Scholar : PubMed/NCBI
18	Jung S, Yi L, Kim J, Jeong D, Oh T, Kim CH, Kim CJ, Shin J, An S and Lee MS: The role of vimentin as a methylation biomarker for early diagnosis of cervical cancer. Mol Cells. 31:405–411. 2011. View Article : Google Scholar : PubMed/NCBI
19	Janssen EA, Øvestad I, Skaland I, Søiland H, Gudlaugsson E, Kjellevold KH, Nysted A, Søreide JA and Baak JP: LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer. Cell Oncol. 31:335–343. 2009.PubMed/NCBI
20	Freise C, Ruehl M, Erben U, et al: A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. BMC Complement Altern Med. 11:392011.PubMed/NCBI
21	Edderkaoui M, Odinokova I, Ohno I, Gukovsky I, Go VL, Pandol SJ and Gukovskaya AS: Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol. 14:3672–3680. 2008. View Article : Google Scholar : PubMed/NCBI
22	MacKenzie L, McCall P, Hatziieremia S, et al: Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Hum Pathol. 43:1491–1500. 2012.
23	Aggarwal BB and Sung B: NF-κB in cancer: a matter of life and death. Cancer Discov. 1:469–471. 2011.